125742 0 20219007.P0

Pfizer Documents (PHMPT/FDA)

Pfizer Bla Submission

Pfizer 16 Plus Documents

18

Download PDF ↗ Live URL (may be dead)

Document text

3DJH 1RI13Reason for Submission
…)RU5HOHDVH
…)RU6XUYHLOODQFH
܈)RU/LFHQVLQJ$FWLRQ
671 B
…&RUUHFWHG3URWRFRO
'DWH $XJ
6XEMHFW(OHFWURQLF3URWRFRO6LJQDWXUH3DJH
/LFHQVH1R 
&RPSDQ\1DPH3KDUPDFLD	8SMRKQ&RPSDQ\//&IRU%LR17HFK0DQXIDFWXULQJ*PE+
3KDUPDFLD	8SMRKQ&RPSDQ\//&IRU%LR17HFK0DQXIDFWXULQJ*PE+KHUHE\VXEPLWVWKH
IROORZLQJORWDVDQHOHFWURQLFVXEPLVVLRQE\(OHFWURQLF6XEPLVV LRQV*DWHZD\(6* $OOWHVW
FRQGXFWHGRQWKLVORWDUHUHSRUWHGDQGSDVVVSHFLILFDWLRQVDVU HTXLUHG
COVID-19 Vaccine, mRNA
(OHFWURQLF3URWRFRO
671 /RW 1XPEHU /RW 7\SH )LOHQDPH
B )) )& 3
6DPSOH6WDWXV
…6DPSOH1RW5HTXLUHG
…6DPSOH6XEPLWWHGZLWK3URWRFRO
܈6DPSOH3UHYLRXV6XEPLWWHG $XJ
9LUXV9HULILFDWLRQ
6RIWZDUH1DPH6\PDQWHF:HE6HFXULW\6HUYLFH
&RPSDQ\1DPH 6\PDQWHF 9HUVLRQ
'DWHRI'HILQLWLRQV $XJ 'DWHRI6FDQ$XJ
,FHUWLI\WKDWWKHVXEPLVVLRQLVYLUXVIUHH
7KHDSSUR[LPDWHILOHVL]HRIWKLVVXEPLVVLRQLV DSSUR[LPDWHO\0%
&RPPHQWV
1$
6LJQDWXUHRI$XWKRUL]HG2IILFLDO
3ULQWHG1DPHDQG7LWOHRI6LJQDWRU\7LWOH
DocUUID : 206efb3b-ea7c-4ed6-a999-e9a921d8b100
bcf9b9f3-dcbe-4cfe-a38a-d0dfba6a6f4c18 Aug 2021 15:47:047-0400
REASON: I approve this document.
(b) (6)
(b) (6)
(b) (6)
FDA-CBER-2021-5683-1150115
3DJH 2RI13Reason for Submission
…)RU5HOHDVH
…)RU6XUYHLOODQFH
܈)RU/LFHQVLQJ$FWLRQ
671 B
…&RUUHFWHG3URWRFRO
cc: 671 )&
/RW1XPEHU))
/LFHQVH1DPHRI3URGXFW&29,'P51$9DFFLQHQXFOHRVLGHPRGL ILHG
0DQXIDFWXUHU1DPH3KDUPDFLD	8SMRKQ&RPSDQ\//&IRU%LR17HFK0D QXIDFWXULQJ*PE+
0DQXIDFWXUHU$GGUHVV3RUWDJH5G.DODPD]RR0,86$
7UDGHQDPH&20,51$7<
'DWHRI0DQXIDFWXULQJ-XO ([SLUDWLRQ'DWH'HF
Fill Information 
Container Type: 9LDO Volume per container: P/
Approved Storage Period: PRQWKV Storage Temperature: ƒ&WRƒ&
Number of containers manufactured:
Number of Dosesper
container:
Number of containers for release:
Volume of singlehuman dose: —J'RVHStartDate of periodof
Validity:'DWHRI
0DQXIDFWXUH
$OOWHVWVFRQGXFWHGRQWKLVORWDUHUHSRUWHGDQGSDVVVSHFLILFDWLRQVDVUHTXLUHG
6LJQDWXUH 'DWH
7LWOH
(OHFWURQLF3URWRFRO3
DocUUID : 206efb3b-ea7c-4ed6-a999-e9a921d8b100
bcf9b9f3-dcbe-4cfe-a38a-d0dfba6a6f4c18 Aug 2021 15:47:047-0400
REASON: I approve this document.
(b) (6)
(b) (6)
(b) (6)
(b) (4)
(b) (4)
FDA-CBER-2021-5683-1150116
3DJ
H3RI13cc: 671  )&
Lot Number: ))
License Name ofProduct: &29,'P51$9DFFLQHQXFOHRVLGHPRGLILHG
Manufacturing Site: 3KDUPDFLD	8SMRKQ&RPSDQ\//&3RUWDJH5G.DODPD]RR0,86$
Date of Manufacture:  -XO Date of Expiry: 'HF
Date of Fill: -XO
Product Information 
&20321(176
Component DescriptionBatch 
NumberDate of 
Manuf.Manufacture Site QuantityTarget 
Concentration
%17E'UXJ
6XEVWDQFH3IL]HU$QGRYHU
%17E'UXJ
6XEVWDQFH3IL]HU$QGRYHU
/13)DEULFDWLRQ3KDUPDFLD	
8SMRKQ&RPSDQ\
//&
%XON'UXJ3URGXFW
)RUPXODWLRQ-XO3KDUPDFLD	
8SMRKQ&RPSDQ\
//&
DocUUID : 206efb3b-ea7c-4ed6-a999-e9a921d8b100
(b) (4)
(b) (4)
(b) (4)
(b) (4)
FDA-CBER-2021-5683-1150117
3DJ
H4RI13cc: 671 )&
Lot Number: ))
License Name ofProduct: &29,'P51$9DFFLQHQXFOHRVLGHPRGLILHG
Table 1. FilledVaccine Quality Control Tests
Test Test Method Specification Date of Test Result
$SSHDUDQFH $SSHDUDQFH9LVXDO:KLWHWRRIIZKLWH
VXVSHQVLRQ0((767(67
$SSHDUDQFH9LVLEOH
3DUWLFXODWHV$SSHDUDQFH3DUWLFOHV0D\FRQWDLQZKLWHWRRII
ZKLWHRSDTXHDPRUSKRXV
SDUWLFOHV0((767(67
6XEYLVLEOH3DUWLFOHV6XEYLVLEOH3DUWLFXODWH
0DWWHU
S+ 
2VPRODOLW\ 2VPRPHWU\ P2VPRONJ
/136L]H'\QDPLF/LJKW
6FDWWHULQJ'/6QP
/133RO\GLVSHUVLW\'\QDPLF/LJKW
6FDWWHULQJ'/6
51$(QFDSVXODWLRQ )OXRUHVFHQFHDVVD\ 
51$FRQWHQW )OXRUHVFHQFHDVVD\ PJP/
$/&FRQWHQW +3/&&$' PJP/
$/&FRQWHQW +3/&&$' PJP/
'63&FRQWHQW +3/&&$' PJP/
&KROHVWHUROFRQWHQW +3/&&$' PJP/
9LDOFRQWHQW &RQWDLQHU&RQWHQW 1RWOHVVWKDQ P/
/LSLGLGHQWLWLHV +3/&&$'5HWHQWLRQWLPHV
FRQVLVWHQWZLWK
UHIHUHQFHV$/& 
$/&&KROHVWHURO
'63&3RVLWLYH
DocUUID : 206efb3b-ea7c-4ed6-a999-e9a921d8b100
(b) (4)
(b) (4)
(b) (4)
(b) (4)
(b) (4)
(b) (4)
(b) (4)
(b) (4)
(b) (4)
(b) (4)
(b) (4)
(b) (4)
(b) (4)
(b) (4)
(b) (4)
FDA-CBER-2021-5683-1150118
3DJ
H5RI13cc: 671 )&
Lot Number: ))
License Name ofProduct: &29,'P51$9DFFLQHQXFOHRVLGHPRGLILHG
Table 1 (Continued) FilledVaccine QualityControlTests
Test Test Method Specification Date of Test Result
,GHQWLW\RIHQFRGHG
51$VHTXHQFH573&5 ,GHQWLW\FRQILUPHG 3RVLWLYH
,Q9LWUR([SUHVVLRQ&HOOEDVHG)ORZ
&\WRPHWU\&HOOV3RVLWLYH
51$,QWHJULW\&DSLOODU\*HO
(OHFWURSKRUHVLVLQWDFW51$
%DFWHULDO(QGRWR[LQ (QGRWR[LQ/$/ (8P/
Abbreviations: /13 /LSLGQDQRSDUWLFOHV&$' FKDUJHGDHURVROGHWHFWRU57 3&5 UHYHUVHWUDQVFULSWLRQ
SRO\PHUDVHFKDLQUHDFWLRQ/$/ /LPXOXVDPHERF\WHO\VDWH(8 HQGRWR[LQXQLW
Filled Vaccine Quality Control Tests (cont.)
Sterility
Method: Type:)LQDO&RQWDLQHU
Container: 6WHULOLW\
Date OnTest Medium/Temperature Date OffTest Specification Test Result
1RJURZWKREVHUYHG 1RJURZWKREVHUYHG
1RJURZWKREVHUYHG 1RJURZWKREVHUYHG
DocUUID : 206efb3b-ea7c-4ed6-a999-e9a921d8b100
(b) (4)
(b) (4)
(b) (4)
(b) (4)
(b) (4)
(b) (4)
(b) (4)
(b) (4)
(b) (4)
(b) (4)
(b) (4)
(b) (4)
FDA-CBER-2021-5683-1150119
3DJ
H6RI13cc: 671 )&
Lot Number: ))
License Name ofProduct: &29,'P51$9DFFLQHQXFOHRVLGHPRGLILHG
FilledVaccine Quality Control Tests(Continued)
Lipid Identity
Specification                Limit             Result    _____Pass
Lipid Standard 
Retention 
Times (RT)Sample 
Retention Time
$/&FRQWHQW
$/&FRQWHQW
'63&FRQWHQW
&KROHVWHUROFRQWHQW
DocUUID : 206efb3b-ea7c-4ed6-a999-e9a921d8b100
(b) (4)
(b) (4)
(b) (4)
FDA-CBER-2021-5683-1150120
3DJ
H7RI13cc: 671 )&
Lot Number: ))
License Name ofProduct: &29,'P51$9DFFLQHQXFOHRVLGHPRGLILHG
FilledVaccine Quality Control Tests(Continued)
RNA encapsulation and content test
Test date                                                        
Test method                BBBB70$BB BBBBBBBBBBBB          
Specification: 51$(QFDSVXODWLRQ         Result    __ ______
Specification: &RQW HQW51$&RQWHQW PJP/ 5HVXOW
Sample/Control Acceptance Criteria Result
5IRU6WDQGDUG $
5IRU6WDQGDUG %
7RWDO51$PJP/
(Q
FDSVXODWHG51$PJP/
DocUUID : 206efb3b-ea7c-4ed6-a999-e9a921d8b100
(b) (4)
(b) (4)
(b) (4)
(b) (4)
(b) (4)
(b) (4)
(b) (4)
FDA-CBER-2021-5683-1150121
3DJ
H8RI13cc: 671 )&
Lot Number: ))
License Name ofProduct: &29,'P51$9DFFLQHQXFOHRVLGHPRGLILHG
FilledVaccine Quality Control Tests(Continued)
Identity of encoded RNA sequence test
Test method                __RT-PCR_________
Test date                                                   
Specification               Identity confirmed              Result    __Positive___
 
Sample/Control Lot number Replicate Ct value Acceptance 
criteriaPass/Fail
'36DPSOH
)) 3DVV


3RVLWLYH3&5&RQWURO  3DVV


3RVLWLYH
&RQWURO3)

'350 3DVV


1HJDWLYH3&5&RQWURO 1$  3DVV


1HJDWLYH
&RQWURO1$  3DVV


 
DocUUID : 206efb3b-ea7c-4ed6-a999-e9a921d8b100
(b) (4)
(b) (4)
(b) (4)
(b) (4)
(b) (4)
FDA-CBER-2021-5683-1150122
3DJ
H9RI13cc: 671 )&
Lot Number: ))
License Name ofProduct: &29,'P51$9DFFLQHQXFOHRVLGHPRGLILHG
FilledVaccine Quality Control Tests(Continued)
In Vitro Expression Assay
Test date                             
Test method                ___Lab-38621______
Specification                cells positive            
Acceptance Criteria Result
/RWQXPEHU
3RVLWLYH&RQWUROORWQXPEHU
 FHOOYLDELOLW\
$YHUDJH1XPEHURI&HOOV&RXQWHGIRU
6DPSOH
7HVW5HVXOWSRVLWLYHFHOOV
DocUUID : 206efb3b-ea7c-4ed6-a999-e9a921d8b100
(b) (4)
(b) (4)
(b) (4)
(b) (4)
(b) (4)
FDA-CBER-2021-5683-1150123
3DJ
H10RI13cc: 671  )&
Lot Number: ))
License Name ofProduct: &29,'P51$9DFFLQHQXFOHRVLGHPRGLILHG
Limulus Amebocyte Lysate Test
&DO
FXODWLRQVRUDGGLWLRQDOFRPPHQWV
N/A
DocUUID : 206efb3b-ea7c-4ed6-a999-e9a921d8b100
(b) (4)
FDA-CBER-2021-5683-1150124
3DJ
H11RI13cc: 671 )&
Lot Number: ))
License Name ofProduct: &29,'P51$9DFFLQHQXFOHRVLGHPRGLILHG
BNT162b2 Drug Substance
Lot Number:
Date of Manufacture: Date of Expiry:
Storage Temperature: Û&WRÛ& Approved Storage Period: PRQWKV
Consumed Quantity:
Table 1. Drug Substance Quality Control Tests
Test Test Method Specification Date of Test Result
&ODULW\ $SSHDUDQFH&ODULW\
&RORUDWLRQ$SSHDUDQFH
&RORUDWLRQ
S+
&RQWHQW51$
&RQFHQWUDWLRQ896SHFWURVFRS\
,GHQWLW\RI(QFRGHG
51$6HTXHQFH573&5
51$,QWHJULW\&DSLOODU\*HO
(OHFWURSKRUHVLV
¶&DS 53+3/&
3RO\$7DLO GG3&5
5HVLGXDO'1$7HPSODWH T3&5
5HVLGXDOGV51$ ,PPXQREORW
%DFWHULDO(QGRWR[LQ (QGRWR[LQ/$/
%LREXUGHQ %LREXUGHQ
Abbreviations: 178 1HSKHORPHWULF7XUELGLW\8QLWV% EURZQ573&5 UHYH UVHWUDQVFULSWLRQSRO\PHUDVH
FKDLQUHDFWLRQGG3&5 GURSOHWGLJLWDO3&5T3&5 TXDQWLWDWLY H3&5GV51$ GRXEOHVWUDQGHG51$
/$/ /LPXOXVDPHERF\WHO\VDWH(8 HQGRWR[LQXQLW&)8 FRORQ\IRUPLQJXQLW
DocUUID : 206efb3b-ea7c-4ed6-a999-e9a921d8b100
(b) (4)
(b) (4)
(b) (4)
(b) (4)
(b) 
(b) (4)
(b) (4)
FDA-CBER-2021-5683-1150125
3DJ
H12RI13cc: 671 )&
Lot Number: ))
License Name ofProduct: &29,'P51$9DFFLQHQXFOHRVLGHPRGLILHG
BNT162b2 Drug Substance
Lot Number:
Date of Manufacture: Date of Expiry:
Storage Temperature: Û&WRÛ& Approved Storage Period: PRQWKV
Consumed Quantity:
Table 1. Drug Substance Quality Control Tests
Test Test Method Specification Date of Test Result
&ODULW\ $SSHDUDQFH&ODULW\
&RORUDWLRQ$SSHDUDQFH
&RORUDWLRQ
S+
&RQWHQW51$
&RQFHQWUDWLRQ896SHFWURVFRS\
,GHQWLW\RI(QFRGHG
51$6HTXHQFH573&5
51$,QWHJULW\&DSLOODU\*HO
(OHFWURSKRUHVLV
¶&DS 53+3/&
3RO\$7DLO GG3&5
5HVLGXDO'1$7HPSODWH T3&5
5HVLGXDOGV51$ ,PPXQREORW
%DFWHULDO(QGRWR[LQ (QGRWR[LQ/$/
%LREXUGHQ %LREXUGHQ
Abbreviations: 178 1HSKHORPHWULF7XUELGLW\8QLWV% EURZQ573&5 UHYH UVHWUDQVFULSWLRQSRO\PHUDVH
FKDLQUHDFWLRQGG3&5 GURSOHWGLJLWDO3&5T3&5 TXDQWLWDWLY H3&5GV51$ GRXEOHVWUDQGHG51$
/$/ /LPXOXVDPHERF\WHO\VDWH(8 HQGRWR[LQXQLW&)8 FROR Q\IRUPLQJXQLW
DocUUID : 206efb3b-ea7c-4ed6-a999-e9a921d8b100
(b) (4)
(b) (4)
(b) 
(b) (4)
(b) (4)
(b) (4)
(b) (4)
FDA-CBER-2021-5683-1150126
Genealogy Flowchart
3DJH 13RI133UHSDUHG%\ $SSURYHG%\
DocUUID : 206efb3b-ea7c-4ed6-a999 e9a921d8b100
bcf9b9f3-dcbe-4cfe-a38a-d0dfba6a6f4c18 Aug 2021 15:47:047-0400
REASON: I approve this document.
ac492be7-205f-4142-8f38-a7ec312471dc18 Aug 2021 16:12:041-0400
REASON: I approve this document.
(b) (6)
(b) (6)
(b) (6)
(b) (6)
(b) (6)
(b) (6)
(b) (4)
FDA-CBER-2021-5683-1150127
Untitled 
Repo
rt Method:  Untitled Date Printed:
125 Saturday, August 14, 2021 Report Method ID:
9 08:20 PM US/Eastern Page: 1 of 1S A M P L E      I N F O R M A T I O N
DocUUID : 206efb3b-ea7c-4ed6-a999-e9a921d8b100
(b) (4)
(b) (4), (b) (6)
FDA-CBER-2021-5683-1150128
Untitled 
Repo
rt Method:  Untitled Date Printed:
125 Saturday, August 14, 2021 Report Method ID:
9 09:12 PM US/Eastern Page: 1 of 1S A M P L E      I N F O R M A T I O N
DocUUID : 206efb3b-ea7c-4ed6-a999-e9a921d8b100
(b) (4)
(b) (4), (b) (6)
FDA-CBER-2021-5683-1150129
Untitled 
Repo
rt Method:  Untitled Date Printed:
125 Saturday, August 14, 2021 Report Method ID:
9 09:37 PM US/Eastern Page: 1 of 1S A M P L E      I N F O R M A T I O N
DocUUID : 206efb3b-ea7c-4ed6-a999-e9a921d8b100
(b) (4)
(b) (4), (b) (6)
FDA-CBER-2021-5683-1150130
FF8841 Replicates 1-3 
DocUUID : 206efb3b-ea7c-4ed6-a999-e9a921d8b100
(b) (4)
FDA-CBER-2021-5683-1150131
DocUUID : 206efb3b-ea7c-4ed6-a999-e9a921d8b100
(b) (4)
FDA-CBER-2021-5683-1150132